Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza vaccine (live attenuated, nasal)
- Development stage
- Approved
- Lead developer
- AstraZeneca
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
Live attenuated influenza vaccine (LAIV) is a vaccine administered as a nasal spray that contains weakened (attenuated) influenza viruses. Unlike inactivated influenza vaccines, LAIV replicates in the mucosa of the upper respiratory tract, mimicking a natural infection to induce a broad immune response, including mucosal IgA, systemic IgG, and cell-mediated immunity. The most widely recognized version is FluMist (known as Fluenz in Europe), which was originally developed by MedImmune and is now part of AstraZeneca's portfolio. It is typically formulated as a quadrivalent vaccine containing two influenza A strains (H1N1 and H3N2) and two influenza B strains (Victoria and Yamagata lineages), with the specific strains updated annually according to World Health Organization (WHO) recommendations.
- Brand names
- FluMistFluenzFluenz TetraNasovac
- Other names
- LAIVLive Attenuated Influenza Vaccinenasal flu vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)RNA-sensing pattern recognition receptorSA (Sialic acid)TCR (T-cell receptor)
Beyond the preview
Go deeper on influenza vaccine (live attenuated, nasal).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza vaccine (live attenuated, nasal).